Assuming a dose-response relationship, personalized dosimetry may allow for applying increased activities of [177Lu]Lu-PSMA-617 resulting in higher tumor doses influencing tumor response rates and potentially patients’ outcome [9,11]. Here, FOLH1 is linked to neoplasm.